Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Georgios Gakis

Showing results (191-200 of 193) with videos related to

Pageof 20
Sort By:
You have reached the last page of results.This site can display upto 193 results.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 20

Showing results (191-200 of 193) with videos related to

Sort By:
Pageof 20
You have reached the last page of results.This site can display upto 193 results.
The Lancet. Oncology|November 23, 2019
Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trialDaniel P Petrylak, Ronald de Wit, Kim N Chi, et al.
European Urology|November 23, 2019
EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort<sup>†</sup>: Under the Auspices of the EAU-ESMO Guidelines CommitteesJ Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
European Urology|May 25, 2020
Corrigendum to 'EAU-ESMO Consensus Statements on the Management of Advanced and Variant Bladder Cancer-An International Collaborative Multistakeholder Effort Under the Auspices of the EAU-ESMO Guidelines Committees' [European Urology 77 (2020) 223-250]J Alfred Witjes, Marek Babjuk, Joaquim Bellmunt, et al.
Pageof 20